A BILL 
To lower the prices of excessively costly life-sustaining pre-
scription drugs under part D of the Medicare program 
by requiring the Secretary of Health and Human Serv-
ices to negotiate their prices, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Life-Sustaining Pre-
4
scription Drug Price Relief Act of 2019’’. 
5
04:35 Nov 21, 2019
H5039
2 
•HR 5039 IH
SEC. 2. IDENTIFICATION OF EXCESSIVELY PRICED LIFE- 
1
SUSTAINING PRESCRIPTION DRUGS. 
2
(a) IN GENERAL.—The Secretary, not later than 1 
3
year after the date of enactment of this Act, shall establish 
4
a process to conduct a review of all life-sustaining pre-
5
scription drugs, not less frequently than once per calendar 
6
year, under which the Secretary determines under sub-
7
section (b) whether the price of each such drug is exces-
8
sive. 
9
(b) EXCESSIVE PRICE DETERMINATIONS.— 
10
(1) INTERNATIONAL REFERENCE PRICE.— 
11
(A) IN GENERAL.—The Secretary shall de-
12
termine that any life-sustaining prescription 
13
drug for which the domestic average manufac-
14
turing price exceeds 110 percent of the average 
15
price charged for such drug in the 5 reference 
16
countries to have an excessive price. In assess-
17
ing the extent to which the price is excessive, 
18
the Secretary shall consider the factors de-
19
scribed in paragraph (2). 
20
(B) REFERENCE COUNTRIES.—In this Act, 
21
the term ‘‘reference countries’’ means Canada, 
22
the United Kingdom, Germany, France, and 
23
Japan. 
24
(C) REQUIREMENT
WITH
RESPECT
TO 
25
DRUGS FOR WHICH CERTAIN REFERENCE COUN-
26
04:35 Nov 21, 2019
H5039
3 
•HR 5039 IH
TRY
INFORMATION
IS
NOT
AVAILABLE.—The 
1
Secretary shall make a determination under 
2
paragraph (1) for every life-sustaining prescrip-
3
tion drug for which pricing information is avail-
4
able for at least 3 of the 5 reference countries. 
5
(2) DETERMINATIONS BASED ON OTHER FAC-
6
TORS.—With respect to any life-sustaining prescrip-
7
tion drug that is not determined to have an excessive 
8
price by operation of paragraph (1) (including any 
9
drug for which there is insufficient data to make 
10
such a determination under such paragraph), the 
11
Secretary shall determine that such drug has an ex-
12
cessive price if the price of the drug is higher than 
13
reasonable taking into account the following factors: 
14
(A) The size of the affected patient popu-
15
lation. 
16
(B) The risk adjusted value of Federal 
17
Government subsidies and investments related 
18
to the drug. 
19
(C) The costs associated with development 
20
of the drug. 
21
(D) Whether the drug provided a signifi-
22
cant improvement in health outcomes, com-
23
pared to other therapies available at the time of 
24
its approval. 
25
04:35 Nov 21, 2019
H5039
4 
•HR 5039 IH
(E) The cumulative global revenues gen-
1
erated by the drug. 
2
(F) Whether the domestic average manu-
3
facturer price of the drug increased during any 
4
annual quarter by a percentage that is more 
5
than the percentage increase in the consumer 
6
price index for all urban consumers for the re-
7
spective annual quarter. 
8
(G) Other factors the Secretary determines 
9
appropriate. 
10
(c) PETITION FOR DETERMINATION.— 
11
(1) IN GENERAL.—Any person may petition the 
12
Secretary, in accordance with section 553(e) of title 
13
5, United States Code, to make an excessive drug 
14
price determination for an applicable drug under 
15
subsection (b)(2). Not later than 90 days after the 
16
date of receipt of such a petition, subject to para-
17
graph (2), the Secretary shall— 
18
(A) make a determination under subsection 
19
(b)(2) regarding such drug; or 
20
(B)(i) decline to make such a determina-
21
tion; and 
22
(ii) make public the reasons why the Sec-
23
retary has declined to make such a determina-
24
tion. 
25
04:35 Nov 21, 2019
H5039
5 
•HR 5039 IH
(2) EXCEPTION.—The Secretary shall not make 
1
a determination under subsection (b)(2) for a drug 
2
in response to a petition under this section more fre-
3
quently than once per calendar year. 
4
(3) 
PUBLIC
AVAILABILITY.—The 
Secretary 
5
shall make any petitions submitted under this sub-
6
section, together with any documentation related to 
7
the petitions and the Secretary’s determinations on 
8
such petitions and rationale for such determinations, 
9
publicly available, including by posting such informa-
10
tion on the database under section 5. 
11
SEC. 3. ABOLISHING THE PROHIBITION ON MEDICARE NE-
12
GOTIATION OF DRUG PRICES AND REQUIR-
13
ING 
THE 
SECRETARY 
OF 
HEALTH 
AND 
14
HUMAN SERVICES TO NEGOTIATE PRICES OF 
15
LIFE-SUSTAINING 
PRESCRIPTION 
DRUGS 
16
FURNISHED UNDER PART D OF THE MEDI-
17
CARE PROGRAM. 
18
Section 1860D–11 of the Social Security Act (42 
19
U.S.C. 1395w–111) is amended by striking subsection (i) 
20
and inserting the following new subsection: 
21
‘‘(i) REQUIREMENT TO NEGOTIATE PRICES WITH 
22
RESPECT TO CERTAIN LIFE-SUSTAINING PRESCRIPTION 
23
DRUGS.— 
24
04:35 Nov 21, 2019
H5039
6 
•HR 5039 IH
‘‘(1) IN GENERAL.—With respect to any life- 
1
sustaining prescription drug (as defined in section 
2
6(4) of the Life-Sustaining Prescription Drug Price 
3
Relief Act of 2019), if the Secretary determines 
4
under section 2 of such Act that the price of the 
5
drug is excessive, the Secretary shall, notwith-
6
standing any other provision of law, negotiate with 
7
manufacturers, prescription drug plan sponsors, and 
8
MA organizations the total payment (including any 
9
discounts, rebates, and other price concessions) that 
10
may be made by such sponsors and organizations 
11
during a negotiated price period (as specified by the 
12
Secretary) for such drugs with respect to such drugs 
13
furnished to individuals who are enrolled under a 
14
prescription drug plan or under an MA–PD plan of-
15
fered by such sponsor or organization, respectively. 
16
‘‘(2) PRICE LIMITATION.—In the case of a life- 
17
sustaining prescription drug that is negotiated by 
18
the Secretary pursuant to paragraph (1), the total 
19
payment described in such paragraph may not ex-
20
ceed 110 percent of the average price charged for 
21
such drug in the 5 reference countries described in 
22
section 2(b)(1)(B) of such Act (in this section re-
23
ferred to as the ‘international reference price’). 
24
‘‘(3) ENFORCEMENT.— 
25
04:35 Nov 21, 2019
H5039
7 
•HR 5039 IH
‘‘(A) IN GENERAL.—In the case of a man-
1
ufacturer of a life-sustaining prescription drug 
2
for which the Secretary has made a determina-
3
tion described in paragraph (1) that fails to 
4
enter into a negotiation and agree on a total 
5
payment with respect to such drugs as de-
6
scribed in such paragraph within 9 months of 
7
such determination— 
8
‘‘(i) if such drug has an international 
9
reference price, the Secretary shall assess 
10
a civil monetary penalty equal to 2 times 
11
the difference between the total revenue for 
12
such drug from all sales in the United 
13
States made beginning after the date that 
14
is 9 months after such determination and 
15
the total revenue for such drug from all 
16
such sales made after such date that would 
17
have been received if the manufacturer 
18
charged the international reference price 
19
for such drug; and 
20
‘‘(ii) if such drug has an international 
21
reference price, the Secretary shall assess 
22
a civil monetary penalty equal to 50 per-
23
cent of the revenue from all United States 
24
sales of the drug in the first 90 days after 
25
04:35 Nov 21, 2019
H5039
8 
•HR 5039 IH
the date that is 9 months after such deter-
1
mination, 75 percent of the value of all 
2
revenue from such sales during the fol-
3
lowing 90 days, and 95 percent of all rev-
4
enue from such sales in subsequent days 
5
until such time as an agreement is reached 
6
or an international reference price is avail-
7
able. 
8
‘‘(B) DEPOSIT INTO TRUST FUND.—Civil 
9
monetary penalties collected pursuant to sub-
10
paragraph (A) shall be deposited into the Fed-
11
eral Hospital Insurance Trust Fund.’’. 
12
SEC. 4. PUBLIC EXCESSIVE DRUG PRICE DATABASE. 
13
(a) EXCESSIVE DRUG PRICE DATABASE.— 
14
(1) IN GENERAL.—The Secretary shall establish 
15
and maintain a comprehensive, up-to-date database 
16
of life-sustaining prescription drugs and the exces-
17
sive price determinations for such drugs under sec-
18
tion 2. 
19
(2) CONTENTS.—The database shall include, at 
20
a minimum, for each life-sustaining prescription 
21
drug, for the applicable calendar year— 
22
(A) the name of the drug; 
23
(B) the manufacturer; 
24
04:35 Nov 21, 2019
H5039
9 
•HR 5039 IH
(C) whether the drug was determined 
1
under section 2(b) to have an excessive price; 
2
and 
3
(D) the number of petitions the Secretary 
4
received under section 2(c) to make an exces-
5
sive price determination for the drug, together 
6
with the information described in section 
7
2(c)(3). 
8
(3) CERTAIN DETERMINATIONS.—With respect 
9
to a determination made under section 2(b)(1), the 
10
Secretary shall publish on the database such deter-
11
mination in accordance with paragraph (1) within 
12
30 days of receiving domestic and international pric-
13
ing information from manufacturers under section 6. 
14
(b) ANNUAL REPORTS
TO CONGRESS.—Not later 
15
than 60 days after the first excessive price review under 
16
section 2 is complete, and annually thereafter, the Sec-
17
retary shall submit to Congress a report describing the 
18
excessive drug price review for the preceding year. The 
19
report shall contain summary data regarding— 
20
(1) the total number of drugs that were re-
21
viewed; 
22
(2) the total number of drugs determined to be 
23
excessively priced under each of paragraphs (1) and 
24
04:35 Nov 21, 2019
H5039
10 
•HR 5039 IH
(2) of section 2(b), and the name and manufacturer 
1
of each such drug; 
2
(3) the total number of drugs determined to be 
3
excessively priced, listed by manufacturer; 
4
(4) the extent to which the prices of the drugs 
5
identified under section 2 were higher than reason-
6
able, on average; 
7
(5) the total number of petitions the Secretary 
8
received under section 2(c) to make excessive price 
9
determinations for drugs; 
10
(6) a list of any manufacturers who failed to re-
11
port information as required under section 6; and 
12
(7) other appropriate information, as the Sec-
13
retary determines or as Congress requests. 
14
(c) PUBLIC
AVAILABILITY.—The Secretary shall 
15
make the information in the database described in sub-
16
section (a) and the report in subsection (b) publicly avail-
17
able, including on the internet website of the Food and 
18
Drug Administration, in a manner that is easy to find and 
19
understand. 
20
SEC. 5. DRUG MANUFACTURER REPORTING. 
21
(a) IN GENERAL.—Each manufacturer shall submit 
22
to the Secretary, in such format as the Secretary may re-
23
quire, an annual report that includes the following infor-
24
04:35 Nov 21, 2019
H5039
11 
•HR 5039 IH
mation for each life-sustaining prescription drug of the 
1
manufacturer, with respect to the previous calendar year: 
2
(1) The average manufacturer price of the drug 
3
in the United States and in the reference countries, 
4
for the entire year, and broken down for each quar-
5
ter of the year. 
6
(2) The wholesale acquisition cost of the drug 
7
in the United States and in the reference countries, 
8
for the entire year, and broken down for each quar-
9
ter of the year. 
10
(3) Cumulative global revenues generated by 
11
the drug. 
12
(4) Annual net sales revenue generated by the 
13
drug in the United States and in the reference coun-
14
tries, for the entire year, and broken down for each 
15
quarter of the year. 
16
(5) Total expenditures on domestic and foreign 
17
drug research and development related to the drug, 
18
itemized by— 
19
(A) basic and preclinical research; 
20
(B) clinical research, reported separately 
21
for each clinical trial; 
22
(C) development of alternative dosage 
23
forms and strengths for the drug molecule or 
24
combinations, including the molecule; 
25
04:35 Nov 21, 2019
H5039
12 
•HR 5039 IH
(D) other drug development activities, such 
1
as nonclinical laboratory studies and record and 
2
report maintenance; 
3
(E) pursuing new or expanded indications 
4
for such drug through supplemental applica-
5
tions under section 505 of the Federal Food, 
6
Drug, and Cosmetic Act; and 
7
(F) carrying out postmarket requirements 
8
related to such drug, including under section 
9
505(o)(3) of the Federal Food, Drug, and Cos-
10
metic Act. 
11
(6) Total expenditures on domestic and foreign 
12
marketing and advertising related to the drug. 
13
(7) Investments in human clinical trials related 
14
to the drug, by each trial and each year, including 
15
grants, research contracts, tax credits or deductions, 
16
and reimbursements from public or private health 
17
plans or insurance, and any other public sector sub-
18
sidies or incentives, such as the fair market value or 
19
priority review vouchers or other considerations. 
20
(8) The estimated size of the affected patient 
21
population. 
22
(9) Additional information the manufacturer 
23
chooses to provide related to drug pricing decisions, 
24
04:35 Nov 21, 2019
H5039
13 
•HR 5039 IH
such as information related to the methodology used 
1
to set the price of the drug. 
2
(10) Additional information as the Secretary 
3
determines necessary to carry out this Act, including 
4
information for previous years. 
5
(b) REPORT DUE DATE.—Applicable manufacturers 
6
shall submit the reports described in subsection (a) not 
7
later than January 15 of the year following the date of 
8
enactment of this Act, and of each year thereafter. 
9
(c) PENALTY FOR NONCOMPLIANCE.— 
10
(1) IN GENERAL.—Any manufacturer that fails 
11
to submit information for a drug as required by this 
12
section on a timely basis or that knowingly provides 
13
false information shall be liable for a civil monetary 
14
penalty, as determined by the Secretary under para-
15
graph (2), in addition to any other penalty under 
16
other applicable provisions of law. 
17
(2) AMOUNT OF PENALTY.—The amount of a 
18
civil penalty under paragraph (1) shall be equal to 
19
the product of— 
20
(A) an amount, as determined appropriate 
21
by the Secretary, which is— 
22
(i) not less than 0.5 percent of the 
23
gross revenues from sales for the previous 
24
04:35 Nov 21, 2019
H5039
14 
•HR 5039 IH
calendar year of the drug for which the in-
1
formation was not submitted; and 
2
(ii) not greater than 1 percent of the 
3
gross revenues from sales for the previous 
4
calendar year of such drug; and 
5
(B) the number of days in the period be-
6
tween— 
7
(i) the report due date under sub-
8
section (b); and 
9
(ii) the date on which the Secretary 
10
receives the information required to be re-
11
ported by the manufacturer under this sec-
12
tion. 
13
(3) USE
OF
CIVIL
PENALTY.—The Secretary 
14
shall collect the civil penalties under this subsection 
15
and shall use such funds to support competitive re-
16
search grant programs of the National Institutes of 
17
Health. 
18
SEC. 6. DEFINITIONS. 
19
For the purposes of this Act: 
20
(1) AVERAGE MANUFACTURER PRICE.— 
21
(A) IN
GENERAL.—The term ‘‘average 
22
manufacturer price’’, with respect to a drug, 
23
subject to subparagraph (B), has the meaning 
24
given such term in section 1927(k)(1) of the 
25
04:35 Nov 21, 2019
H5039
15 
•HR 5039 IH
Social Security Act (42 U.S.C. 1396r–8(k)(1)); 
1
or with respect to a drug for which there is no 
2
average manufacturer price as so defined, such 
3
term shall mean the wholesale acquisition cost 
4
(as defined in section 1847A(c)(6)(B) of the 
5
Social 
Security 
Act 
(42 
U.S.C. 
1395w– 
6
3a(c)(6)(B)) of the drug. 
7
(B) APPLICATION TO REFERENCE COUN-
8
TRIES.—With respect to reference countries, 
9
the term ‘‘average manufacturer price’’, as de-
10
fined in subparagraph (A), shall be determined 
11
based on the price of the drug in the applicable 
12
reference country. 
13
(2) BIOSIMILAR
BIOLOGICAL
PRODUCT.—The 
14
term ‘‘biosimilar biological product’’ means a biologi-
15
cal product licensed pursuant to an application 
16
under section 351(k) of the Public Health Service 
17
Act (42 U.S.C. 262(k)). 
18
(3) GENERIC DRUG.—The term ‘‘generic drug’’ 
19
means a drug approved pursuant to an application 
20
under section (b)(2) or (j) of the Federal Food, 
21
Drug, and Cosmetic Act (21 U.S.C. 355). 
22
(4) LIFE-SUSTAINING
PRESCRIPTION
DRUG.— 
23
The term ‘‘life-sustaining prescription drug’’ means 
24
a drug that is— 
25
04:35 Nov 21, 2019
H5039
16 
•HR 5039 IH
(A) approved under subsection (c) or (j) of 
1
section 505 of the Federal Food, Drug, and 
2
Cosmetic Act (21 U.S.C. 355) or a biological 
3
product licensed under subsection (a) or (k) of 
4
section 351 of the Public Health Service Act 
5
(42 U.S.C. 262); 
6
(B) subject to section 503(b)(1) of the 
7
Federal Food, Drug, and Cosmetic Act (21 
8
U.S.C. 353(b)(1)); and 
9
(C) life-sustaining (as such term is defined 
10
in regulation pursuant to section 506C of the 
11
Federal Food, Drug, and Cosmetic Act (21 
12
U.S.C. 356c)). 
13
(5) MANUFACTURER.—The term ‘‘manufac-
14
turer’’ means the holder of an application approved 
15
under section 505 of the Federal Food, Drug, and 
16
Cosmetic Act (21 U.S.C. 355) or of a license issued 
17
under section 351 of the Public Health Service Act 
18
(42 U.S.C. 262). 
19
(6) SECRETARY.—The term ‘‘Secretary’’ means 
20
the Secretary of Health and Human Services. 
21
Æ 
04:35 Nov 21, 2019
H5039
